



STAR PHARMACEUTICAL LIMITED
(Company Registration No. 200500429W)
(Incorporated in Singapore)

QUARTERLY UPDATE PURSUANT TO RULE 1313 (2) OF THE LISTING MANUAL OF THE SINGAPORE EXCHANGE SECURITIES TRADING LIMITED (“SGX-ST”)

The Board of Directors (the “**Board**”) of Star Pharmaceutical Limited (the “**Company**”, and together with its subsidiaries, collectively the “**Group**”) refers to its announcement dated 5 June 2017 that the Company was placed on the watch-list due to the Minimum Trading Price (the “**MTP**”) Entry Criterion with effect from 5 June 2017.

Pursuant to Rule 1313(2) of the Listing Manual of the SGX-ST, the Board wishes to provide an update as follows:

- (1) The Company will continue with its efforts and consider various options to meet the requirements of Rule 1314(2) of the Listing Manual of the SGX-ST pursuant to the MTP exit criterion and will update its shareholders in due course.
- (2) The Company has on 14 November 2017 released its unaudited financial statements for the period ended 30 September 2017 via the SGXNet which provides an update on the Group’s financial position. The Company will update shareholders of the Company if there are any material developments that may impact the Group’s financial position.

The Company will make further announcements to update shareholders of the Company as and when there are any material developments in this matter.

By Order of the Board

Xu Zhi Bin
Executive Chairman
16 November 2017